{"id":45997,"date":"2025-11-06T14:22:19","date_gmt":"2025-11-06T06:22:19","guid":{"rendered":"https:\/\/flcube.com\/?p=45997"},"modified":"2025-11-06T14:22:20","modified_gmt":"2025-11-06T06:22:20","slug":"xtalpis-ailux-strikes-345-million-partnership-with-eli-lilly-to-co%e2%80%91develop-bispecific-antibodies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45997","title":{"rendered":"XtalPi\u2019s Ailux Strikes $345\u202fMillion Partnership with Eli\u202fLilly to Co\u2011Develop Bispecific Antibodies"},"content":{"rendered":"\n

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228<\/a>)<\/strong> disclosed that its wholly\u2011owned subsidiary Ailux<\/strong> has entered a multi\u2011year collaboration with Eli Lilly and Company<\/strong> (NYSE: LLY<\/a>). The agreement is valued at USD\u202f345\u202fmillion<\/strong>, with upfront and near\u2011term cash payments running into the double\u2011digit\u2011million range.<\/p>\n\n\n\n

Deal Highlights<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Parties<\/strong><\/td>XtalPi\u2019s AI\u2011driven antibody platform (Ailux) \u2013\u202fEli\u202fLilly<\/td><\/tr>
Total Value<\/strong><\/td>USD\u202f345\u202fmillion (up\u2011front + milestone payments)<\/td><\/tr>
Up\u2011Front Cash<\/strong><\/td>Double\u2011digit\u2011million USD paid at signing<\/td><\/tr>
Scope<\/strong><\/td>Access to Ailux\u2019s engineering platform for bispecific antibody programs across multiple therapeutic targets; optional license of Ailux\u2019s AI\u2011driven discovery engine for Lilly\u2019s internal use<\/td><\/tr>
Historical Context<\/strong><\/td>Lilly previously partnered with XtalPi in 2023 on a small\u2011molecule discovery program worth up to USD\u202f250\u202fmillion<\/td><\/tr>
Commercial Timeline<\/strong><\/td>First target selection expected Q2\u202f2026; IND\u2011enabling studies to begin Q4\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n
    \n
  1. Accelerated Antibody Innovation<\/strong> \u2013 Ailux\u2019s proprietary engineering platform integrates AI\u2011guided sequence design, rapid in\u2011silico affinity maturation, and high\u2011throughput expression, shortening bispecific antibody development cycles from years to months.<\/li>\n\n\n\n
  2. Portfolio Diversification for XtalPi<\/strong> \u2013 Moving beyond small\u2011molecule discovery, the partnership expands XtalPi\u2019s addressable market into the high\u2011margin biologics space, leveraging its AI core across modalities.<\/li>\n\n\n\n
  3. Lilly\u2019s Pipeline Enrichment<\/strong> \u2013 The collaboration provides Lilly with a ready\u2011made platform to generate next\u2011generation bispecifics for oncology, immunology, and rare diseases, complementing its existing antibody assets.<\/li>\n<\/ol>\n\n\n\n

    Financial & Market Impact<\/h2>\n\n\n\n